+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Comments

Loading...

Appili Therapeutics

APLIFOTCPK

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.025000

0.003315.21%

At Close: -

15 minutes delayed

Appili Therapeutics (APLIF) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Appili Therapeutics (OTC:APLIF) Stock

Appili Therapeutics Stock (OTC: APLIF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, July 25, 2024

Aditxt Signs Second Amendment To The Arrangem...
Benzinga Newsdesk

Tuesday, September 06, 2022

APLIF: Advancing Multiple Programs to Combat Infectious Diseases…
Zacks Small Cap Research

Thursday, July 14, 2022

APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…
Zacks Small Cap Research

Thursday, March 03, 2022

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…
Zacks Small Cap Research

Tuesday, December 28, 2021

Aditxt Signs Share Exchange Agreement to Acquire AiPharma in Cash, Stock Deal
Charles Gross

Monday, November 29, 2021

APLIF: PRESECO Trial Unsuccessful in COVID-19…
Zacks Small Cap Research

Friday, November 05, 2021

A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Dana Salzarulo - Sponsored

Thursday, October 28, 2021

Is Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral?
Dana Salzarulo - Sponsored

Tuesday, October 05, 2021

Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate
Vandana Singh

Wednesday, September 01, 2021

APLIF: Awaiting Data Readout for Phase 3 PRESECO Trial in COVID-19…
Zacks Small Cap Research

Monday, June 28, 2021

APLIF: DSMB Recommends for PRESECO Trial to Complete; Data Expected in 3Q21…
Zacks Small Cap Research

Monday, May 03, 2021

Appili Pharmaceuticals ($APLIF): The Last COVID-19 Stock With Massive Upside - Under $50 Million Market Cap
Willow Research

Tuesday, November 24, 2020

Health Canada Clears Appili Therapeutics For ...
Benzinga Newsdesk

Friday, October 30, 2020

Appili Therapeutics Signs Collaboration, Deve...
Benzinga Newsdesk

Monday, August 10, 2020

FDA Clears Appili Therapeutics to Expand its ...
Luke J Jacobi

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved